Q-omics provides the consensus-scored RSPO2 profile across patient tissues and cancer cell-line models. RSPO2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RSPO2 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, RSPO2 RNA expression shows 13,382 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where RSPO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPO2 survival associations across molecular data types. RSPO2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPO2 RNA expression–survival associations across cancer types. High RSPO2 expression shows unfavorable associations in KIRC, ACC, BLCA and READ, but favorable associations in SKCM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for RSPO2 RNA expression.
This table summarizes RSPO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RSPO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPO2 shows lower tumor expression in LUAD, COAD, LUSC, READ, STAD and BLCA. The LUAD box plot shows higher RSPO2 RNA expression in normal versus tumor tissue (log2 FC = −2.493, t-test p < 0.001).
This table shows molecular features associated with RSPO2 in patient tissues and cancer cell lines. In patient samples, RSPO2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
